Annexon, Inc. Files 8-K Report
Ticker: ANNX · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1528115
Sentiment: neutral
Topics: reporting, financials
TL;DR
Annexon filed an 8-K, mostly boilerplate financial docs, no major news.
AI Summary
On December 16, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided excerpt. The company is incorporated in Delaware and its principal executive offices are located in Brisbane, California.
Why It Matters
This 8-K filing indicates Annexon, Inc. is fulfilling its reporting obligations with the SEC, primarily related to financial statements and exhibits, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Numbers
- 20241216 — Report Date (Date of the earliest event reported)
Key Players & Entities
- Annexon, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Brisbane, California (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Annexon, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the filing's content.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 16, 2024.
Where are Annexon, Inc.'s principal executive offices located?
Annexon, Inc.'s principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.
In which state is Annexon, Inc. incorporated?
Annexon, Inc. is incorporated in Delaware.
Does this 8-K filing disclose any specific new material events or transactions?
Based on the provided excerpt, this 8-K filing primarily concerns financial statements and exhibits and does not detail any specific new material events or transactions.
Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-12-16 07:46:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Mar
Filing Documents
- d909577d8k.htm (8-K) — 25KB
- d909577dex991.htm (EX-99.1) — 25KB
- 0001193125-24-279038.txt ( ) — 182KB
- annx-20241216.xsd (EX-101.SCH) — 3KB
- annx-20241216_lab.xml (EX-101.LAB) — 18KB
- annx-20241216_pre.xml (EX-101.PRE) — 11KB
- d909577d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 16, 2024, titled "Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS)." 104 Cover Page Interactive Data File, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 16, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer